- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Revenue from operations for SMS Pharmaceuticals Limited reached ₹173.35 crore in Q3FY25, reflecting a 7% year-on-year growth, driven by heightened product demand. The company experienced a significant expansion in gross profit margins, which improved to 39%, up 729 basis points year-on-year. EBITDA rose by 15% to ₹33.21 crore, with EBITDA margins now at 19%. Profit after tax (PAT) surged by 59% to ₹18.24 crore due to reduced finance costs.
Looking ahead, SMS Pharma aims to enhance its competitive edge through the completion of its backward integration project, expected to start commercial production in March 2025. This initiative is anticipated to positively impact margins starting FY26. The company remains focused on scaling its production capacities and reinforcing its market position in the API sector. Overall, SMS Pharma shows a positive outlook, supported by recent client acquisitions and operational improvements.